By Josh White
Date: Monday 18 Aug 2025
(Sharecast News) - Faron Pharmaceuticals said on Monday that it has secured a clear regulatory pathway for the potential approval of its lead cancer therapy bexmarilimab, following positive feedback from the US Food and Drug Administration.
Holding(s) in Company | 18-Aug-2025 | 15:44 | RNS |
Director/PDMR Shareholding | 18-Aug-2025 | 15:00 | RNS |
Notice of Results | 18-Aug-2025 | 07:00 | RNS |
Commercial Progress in USA | 18-Aug-2025 | 07:00 | RNS |
Contract extension with global pharma partner | 18-Aug-2025 | 07:00 | RNS |
Questor :GW Pharmaceuticals | 04-Dec-2014 | Telegraph |
Questor : Hikma Pharmaceuticals | 13-Mar-2014 | Telegraph |
Investment Column:BTG | 06-Oct-2011 | The Independent |
Investment Column:Genus | 09-Sep-2011 | The Independent |
Questor :Dechra Pharmaceuticals | 08-Sep-2011 | Telegraph |
Price | 21,870.27 |
Closing Price Change | 252.75 |
% Change | 1.17 % |
18-Aug-25 Close | 21,870.27 |
You are here: research